The AI-driven biotech has secured FDA alignment on a pivotal trial for its FAP therapy, with a study start planned for 2027.
If you picked Recursion Pharmaceuticals for its AI-first pitch and deep pharma ties, the past year has probably felt rough.
This pharmaceutical-development technology company continues to demonstrate that its testing platform has real potential.
On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though ...
Recursion announces FDA alignment for REC-4881’s Phase 3 trial in familial adenomatous polyposis, targeting crucial adenoma excision outcomes.
Recursion Pharmaceuticals, Inc. ( RXRX) announced Wednesday that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the design of its registrational Phase 3 trial of REC-4881 ...
Learn how to make your docs AI-readable with llms.txt, llms-full.txt, clean Markdown, and semantic structure, so AI tools and ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
RXRX is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.10 since the market last closed. This is a 3.72% ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...